Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan, China.
Department of Anesthesiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Biomed Pharmacother. 2024 Oct;179:117383. doi: 10.1016/j.biopha.2024.117383. Epub 2024 Sep 3.
Ischemic heart disease (IHD) is a significant global health concern, resulting in high rates of mortality and disability among patients. Although coronary blood flow reperfusion is a key treatment for IHD, it often leads to acute myocardial ischemia-reperfusion injury (IRI). Current intervention strategies have limitations in providing adequate protection for the ischemic myocardium. DJ-1, originally known as a Parkinson's disease related protein, is a highly conserved cytoprotective protein. It is involved in enhancing mitochondrial function, scavenging reactive oxygen species (ROS), regulating autophagy, inhibiting apoptosis, modulating anaerobic metabolism, and exerting anti-inflammatory effects. DJ-1 is also required for protective strategies, such as ischemic preconditioning, ischemic postconditioning, remote ischemic preconditioning and pharmacological conditioning. Therefore, DJ-1 emerges as a potential target for the treatment of myocardial IRI. Our comprehensive review delves into its protective mechanisms in myocardial IRI and the structural foundations underlying its functions.
缺血性心脏病（IHD）是一个重大的全球健康问题，导致患者死亡率和残疾率居高不下。虽然冠状动脉血流再灌注是 IHD 的关键治疗方法，但它常常导致急性心肌缺血再灌注损伤（IRI）。目前的干预策略在为缺血心肌提供充分保护方面存在局限性。DJ-1 最初是一种与帕金森病相关的蛋白，是一种高度保守的细胞保护蛋白。它参与增强线粒体功能、清除活性氧（ROS）、调节自噬、抑制细胞凋亡、调节无氧代谢和发挥抗炎作用。DJ-1 还需要保护策略，如缺血预处理、缺血后处理、远程缺血预处理和药物预处理。因此，DJ-1 成为治疗心肌 IRI 的潜在靶点。我们的综合综述深入探讨了它在心肌 IRI 中的保护机制及其功能的结构基础。
